Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention

Journal of Alzheimer's Disease

Volumn 50, Issue 3, 2016, Pages 779-789

  Nation, Daniel A ^a   Ho, Jean ^a   Yew, Belinda ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amyloid ; antihypertensive medications; AT1 receptor blockers; blood pressure; CSF biomarkers; tau

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TAU PROTEIN; TELMISARTAN; VALSARTAN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK FACTOR; AGING; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; LONGITUDINAL STUDY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; TAU PROTEINS; TIME FACTORS;

EID: 84957899869     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150487     Document Type: Article

References (46)

1. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145.
2. Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, Quinn JF, Galasko DR (2013) Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology 81, 2024-2027.
3. NationDA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, Edland SD, Salmon DP, Galasko DR, Bondi MW, Alzheimer's Disease Neuroimaging Initiative (2015) Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol 72, 546-553.
4. Qiu C (2012) Preventing Alzheimer's disease by targeting vascular risk factors: Hope and gap. J Alzheimers Dis 32, 721-731.
5. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C,Waldman A,Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C, HYVET investigators (2008) Incident dementia and blood pressure lowering in the Hypertension in theVery ElderlyTrial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol 7, 683-689.
6. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhager WH (2011) Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 57, e6-e7.
7. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340, b5465.
8. Chiu WC, Ho WC, Lin MH, Lee HH, Yeh YC, Wang JD, Chen PC, Health Data Analysis in Taiwan (hDATa) Research, Group (2014) Angiotension receptor blockers reduce the risk of dementia. J Hypertens 32, 938-947.
9. Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, Sedefdjian A, Sevenier F, Shlyakhto EV, Pathak A (2008) Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: Primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens 26, 1642-1650.
10. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26, 699-708.
11. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T (2012) Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 12, 207-214.
12. Hajjar I, Hart M, Chen YL, Mack W, Milberg W, Chui H, Lipsitz L (2012) Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: A double-blind randomized clinical trial. Arch Intern Med 172, 442-444.
13. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-LeviAC,Maison P (2013) Antihypertensive classes, cognitive decline and incidence of dementia: A network meta-analysis. J Hypertens 31, 1073-1082.
14. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM (2007) Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117, 3393-3402.
15. Liu J, Liu S, Tanabe C, Maeda T, Zou K, Komano H (2014) Differential effects of angiotensin II receptor blockers on Abeta generation. Neurosci Lett 567, 51-56.
16. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M (2008) Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 375, 446-449.
17. Zhu D, Shi J, Zhang Y, Wang B, Liu W, Chen Z, Tong Q (2011) Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats. PLoS One 6, e16037.
18. Tian M, Zhu D, Xie W, Shi J (2012) Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett 586, 3737-3745.
19. Hajjar I, Brown L, Mack WJ, Chui H (2012) Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 69, 1632-1638.
20. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S,Kehoe PG (2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 34, 181-193.
21. Miners JS, Palmer JC, Tayler H, Palmer LE, Ashby E, Kehoe PG, Love S (2014) Abeta degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. Front Aging Neurosci 6, 238.
22. Jochemsen HM, van der Flier WM, Ashby EL, Teunissen CE, Jones RE,Wattjes MP, Scheltens P, Geerlings MI, Kehoe PG, MullerM (2015) Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. J Alzheimers Dis 44, 153-162.
23. Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, Scheltens P, Kehoe PG, Muller M (2014) The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimers Res Ther 6, 27.
24. Ashby EL, Kehoe PG (2013) Current status of reninaldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin Investig Drugs 22, 1229-1242.
25. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 136, 2697-2706.
26. Hughes TM, Kuller LH, Barinas-Mitchell EJ, Mackey RH, McDade EM, Klunk WE, Aizenstein HJ, Cohen AD, Snitz BE, Mathis CA, Dekosky ST, Lopez OL (2013) Pulse wave velocity is associated with beta-amyloid deposition in the brains of very elderly adults. Neurology 81, 1711-1718.
27. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Amyloid Biomarker Study G, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Forster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Kohler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonca A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Mollergard HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder J, Schutte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313, 1924-1938.
28. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW (2010) Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 74, 201-209.
29. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
30. Alsop DC, DaiW, Grossman M, Detre JA (2010) Arterial spin labeling blood flow MRI: Its role in the early characterization of Alzheimer's disease. J Alzheimers Dis 20, 871-880.
31. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB (1994) Stroke risk profile: Adjustment for antihypertensive medication. The Framingham Study. Stroke 25, 40-43.
32. Rodrigue KM, Rieck JR,Kennedy KM, DevousMDSr, Diaz-Arrastia R, Park DC (2013) Risk factors for beta-amyloid deposition in healthy aging: Vascular and genetic effects. JAMA Neurol 70, 600-606.
33. Vidoni ED, Townley RA, Honea RA, Burns JM, Alzheimer's Disease Neuroimaging Initiative (2011) Alzheimer disease biomarkers are associated with body mass index. Neurology 77, 1913-1920.
34. Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, Schnur E, Santoro J, Davis KL (1999) CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 52, 547-551.
35. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V (2009) Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72, 1720-1726.
36. Wright JW, HarDing JW (2010) The brain RAS and Alzheimer's disease. Exp Neurol 223, 326-333.
37. Villapol S, Saavedra JM (2015) Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 28, 289-299.
38. Mogi M, HoriuchiM (2009) Effects of angiotensin II receptor blockers on dementia. Hypertens Res 32, 738-740.
39. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgammaagonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
40. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24, 10908-10917.
41. Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, Xie L, Kang H, Xu Q, Liew JA, Plog BA, Ding F, Deane R, Nedergaard M (2014) Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 76, 845-861.
42. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
43. Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW, Alzheimer's Disease Neuroimaging I (2014) Association of brain amyloid-beta with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain 137, 1550-1561.
44. Hajjar I, Hart M, Chen YL, Mack W, Novak V, Chui CH, Lipsitz L (2013) Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: Results of a pilot randomized clinical trial. J Am Geriatr Soc 61, 194-201.
45. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, Kano M, Ogihara T, Rakugi H, Morishita R (2009) Angiotensin receptor blocker prevented beta-amyloidinduced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54, 1345-1352.
46. Weber MA, Schiffrin EL, White WB,Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB (2014) Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32, 3-15.